First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry

Droz J., Efstathiou E., Yildirim A., Cabrera P., Kim C. S., Horchani A., ...More

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, vol.34, no.5, 2016 (SCI-Expanded) identifier identifier identifier


Aims: To compare the efficacy and tolerability of taxane and nontaxane therapy in senior adults with chemonaive metastatic castration resistant prostate cancer (mCRPC), and examine the effect of patient health status on outcomes.